

# Prof. dr. Olaf H. Klungel

O. H. Klungel is Professor of Pharmacoepidemiologic Methods and chair of the division of Pharmacoepidemiology & Clinical Pharmacology. He was trained as a pharmacist and epidemiologist. His main research area is the development, improvement and evaluation of innovative methods of observational drug research. Main applications are in the post-registration phase of drug development. Prof. Klungel represents the division of Pharmacoemidemiology & Clinical Pharmacology in the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), the IMI-EU2P steering committee (Director of Benefit/Risk Assessment domain), and is PI of the EU Pharmacoepidemiology & Pharmacovigilance Research Network (formerly PROTECT). He is also member of the Steering Committee of ENCePP and the Board of the International Society of Pharmacoepidemiology (ISPE) representing Academic Europe/Africa. Selected research findings on benefits and harms of medicines include the impact of genetic variants in the renin-angiotensin and salt-sensitivity system on the risk of type 2 diabetes mellitus and myocardial infarction associated with the use of thiazide diuretics and ACE inhibitors, the discovery that thiazide diuretics have a particular beneficial effect compared to other antihypertensive drugs in the prevention of the risk of ischemic stroke (research performed at University of Washington in Seattle, US in collaboration with Prof. Bruce Psaty). More recent findings include the increased risk of autoimmune diseases such as rheumatoid arthritis and lupus-like syndrome associated with the use of statins and increased bleeding risk with concurrent use of selective serotonin inhibitors and coumarins. In addition to his research, Prof. Klungel teaches pharmacoepidemiology and pharmacotherapy to medical and pharmacy students. He is (co-)author of over 260 papers in peer reviewed journals, book chapters and research reports.

<https://www.uu.nl/staff/OHKlungel/0>